ArticleMolecular therapy. Nucleic acids2020
Characterization of Circular RNAs in Vascular Smooth Muscle Cells with Vascular Calcification.
Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- The Protein Histidine Methyltransferase METTL9-From Mechanism to Biological Function.Life (Basel, Switzerland) · 2026Review
- Circular RNAs in Cardiovascular Physiopathology: From Molecular Mechanisms to Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Exploring the role of circ-GALK2 in vascular smooth muscle cell calcification: mechanisms and implications.European journal of medical research · 2025Article
- Circular RNA role in Atherosclerosis Development and Progression.Current atherosclerosis reports · 2025Review
- Functions and application of circRNAs in vascular aging and aging-related vascular diseases.Journal of nanobiotechnology · 2025Review
- Endothelial cells derived extracellular vesicles promote diabetic arterial calcification via circ_0008362/miR-1251-5p/Runx2 axial.Cardiovascular diabetology · 2024Article
- Noncoding RNAs in atherosclerosis: regulation and therapeutic potential.Molecular and cellular biochemistry · 2024Review
- Circular RNA circSMAD4 regulates cardiac fibrosis by targeting miR-671-5p andMolecular therapy. Nucleic acids · 2023Article
- CircHIPK3 relieves vascular calcification via mediating SIRT1/PGC-1α/MFN2 pathway by interacting with FUS.BMC cardiovascular disorders · 2023Article
- Dynamic observation of circRNA and mRNA profiles in a rat model of deep vein thrombosis.Experimental and therapeutic medicine · 2023Article
- RNA binding protein SAMD4: current knowledge and future perspectives.Cell & bioscience · 2023Review
- Extracellular vesicles in atherosclerosis and vascular calcification: the versatile non-coding RNAs from endothelial cells and vascular smooth muscle cells.Frontiers in medicine · 2023Review
- Circular RNA circSmoc1-2 regulates vascular calcification by acting as a miR-874-3p sponge in vascular smooth muscle cells.Molecular therapy. Nucleic acids · 2022Article
- Emerging Roles of Extracellular Vesicle-Delivered Circular RNAs in Atherosclerosis.Frontiers in cell and developmental biology · 2022Review
- CircSamd4: A novel biomarker for predicting vascular calcification.Journal of clinical laboratory analysis · 2022Article
- Circular RNAs in kidney disease and cancer.Nature reviews. Nephrology · 2021Review
- MicroRNAs in Valvular Heart Diseases: Biological Regulators, Prognostic Markers and Therapeutical Targets.International journal of molecular sciences · 2021Review
- Circular RNAs: Expression, localization, and therapeutic potentials.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Role of gut microbiota-derived metabolites on vascular calcification in CKD.Journal of cellular and molecular medicine · 2021Review
- Circular RNAs as Novel Diagnostic Biomarkers and Therapeutic Targets in Kidney Disease.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) are generally formed by back splicing and are expressed in various cells. Vascular calcification (VC), a common complication of chronic kidney disease (CKD), is often associated with cardiovascular disease. The relationship between circRNAs and VC has not yet been studied. Inorganic phosphate (Pi) was used to treat rat vascular smooth muscle cells to induce VC. circRNAs were identified by analyzing RNA sequencing (RNA-seq) data, and their expression change during VC was validated. The selected circRNAs, including circSamd4a, circSmoc1-1, circMettl9, and circUxs1, were resistant to RNase R digestion and mostly localized in the cytoplasm. While silencing circSamd4a promoted VC, overexpressing it reduced VC in calcium assay and Alizarin red S (ARS) staining. In addition, microRNA (miRNA) microarray, luciferase reporter assay, and calcium assay suggested that circSamd4a could act as a miRNA suppressor. Our data show that circSamd4a has an anti-calcification role by functioning as a miRNA sponge. Moreover, mRNAs that can interact with miRNAs were predicted from RNA-seq and bioinformatics analysis, and the circSamd4a-miRNA-mRNA axis involved in VC was verified by luciferase reporter assay and calcium assay. Since circSamd4a is conserved in humans, it can serve as a novel therapeutic target in resolving VC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.